ASCO 2023: Cancer experts gather in Chicago

From 2-6 June many scientists from The Institute of Cancer Research, London, will join a global forum of world-leading scientists and oncologists at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.

A global highlight of the cancer research calendar, ASCO sees the latest, practice-changing results from major phase III trials presented alongside exciting early phase trial results, translational research, and insightful commentary on all aspects of oncology.

This year’s theme is Partnering with Patients: The Cornerstone of Cancer Care and Research and the meeting will focus on better, more equitable cancer care, and the importance of meaningful relationships between oncologists and patients.

Keep reading for a summary of studies being presented by researchers from the ICR and our partners The Royal Marsden NHS Foundation Trust at ASCO 2023. 

To access the full programme with specific timings and locations visit the ASCO website.

Presentations

Friday 2 June

Oral presentations:

• Detection of circulating tumor DNA following neoadjuvant chemotherapy and surgery to anticipate early relapse in ER positive and HER2 negative breast cancer: Analysis from the PENELOPE-B trial.
  Nicholas Turner
  Oral abstract number: 502
  14:45

Saturday 3 June

Poster presentations:

• A phase (Ph) I/II trial of abiraterone acetate in combination with tildrakizumab (anti-IL23 monoclonal antibody) in patients with metastatic castration-resistant prostate cancer (mCRPC).
  Christina Guo
  Abstract: TPS5105
  Poster Bd #: 195b
  08:00
  
  
• Lisavanbulin in patients with recurrent glioblastoma: Phase 2a results and a consolidated analysis of response-predictive biomarkers.
  Juanita Lopez
  Abstract: 2044
  Poster Bd #: 401
  13:15
  
  
• Phase 1 trial of avelumab with hypofractionated thoracic radiation therapy (HT-RT) in patients with metastatic soft-tissue sarcomas (mSTS).
  Shane H Zaidi
  Abstract: 11552
  Poster Bd #: 486
  13:15
  
  
• The Man Van: Mobile targeted case finding for prostate cancer.
  Masood Moghul
  Abstract: 6522
  Poster Bd #: 14
  13:15
  
  
• CONSENT: Randomized controlled trial of enhanced informed consent compared to standard informed.
  Abhijit Pal
  Abstract: 6560
  Poster Bd #: 52
  13:15
  
  
• Overall survival and long-term safety in patients with advanced gastrointestinal stromal tumor previously treated with imatinib: Updated analyses from INTRIGUE.
  Robin Jones
  Abstract: 11524
  Poster Bd #: 458
  16:30

Sunday 4 June

Poster presentations:

• Subcutaneous amivantamab (ami) in patients (pts) with advanced solid malignancies: The PALOMA study—Updated safety and identification of the recommended phase 2 dose.
  Anna Minchom
  Abstract: 9126
  Poster Bd #: 114
  08:00
  
  
• Randomised open-label phase II study of induction standard of care fulvestrant and CDK4/6 inhibition with addition of ipatasertib in metastatic ER+/HER2- breast cancer patients without circulating tumour (ct) DNA suppression (FAIM).
  Alicia Okines
  Abstract: TPS1111
  Poster Bd #: 332a
  08:00

Monday 5 June

Oral presentations:

• Jumping Ahead, Falling Behind, or Standing Still in the Frontline Setting for Advanced Melanoma?
  James Larkin
  15:00
  
  
• State-of-the-Art Management of Biliary Tract Cancers – The Medical Oncologist's Perspective.
  Naureen Starling
  16:30

Poster presentations:

• A phase 2, open-label, multicenter study investigating efficacy and safety of RP3 oncolytic immunotherapy combined with other therapies in patients with locoregionally advanced or recurrent squamous cell carcinoma of the head and neck.
  Kevin Harrington
  Abstract: TPS6106
  Poster Bd #: 95b
  13:15
  
  
• Prognostic factors of early mortality in children and adolescents enrolled in oncology trials with a dose-finding part in the era of targeted and immune therapies: An Innovative Therapies for Children with Cancer (ITCC) study.
  Fernando Carceller
  Abstract: 10020
  Poster Bd #: 326
  16:30
  
  
• Initial efficacy and safety results from ENGOT-ov60/GOG-3052/RAMP 201: A phase 2 study of avutometinib (VS-6766) ± defactinib in recurrent low-grade serous ovarian cancer (LGSOC).
  Susana Banerjee
  Abstract: 5515
  Poster Bd #: 210
  16:30

Join the conversation on social media with the hashtag #ASCO23.

Read more news and stories from the ASCO Annual Meeting.

ASCO Annual Meeting